News from janssen biotech, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Sep 27, 2018, 06:00 ET Janssen Elects Not to Continue Agreement with Geron for Imetelstat

Janssen Biotech, Inc. (Janssen) announced today its decision not to continue the collaboration and license agreement with Geron Corporation for...

Dec 21, 2017, 16:00 ET Janssen Enters Worldwide Collaboration and License Agreement with Chinese Company Legend Biotech to Develop Investigational CAR-T Anti-Cancer Therapy

Janssen Biotech, Inc. ("Janssen"), a Janssen Pharmaceutical Company of Johnson & Johnson, announced today that it has entered into a worldwide...

Dec 21, 2017, 07:00 ET U.S. FDA Grants Priority Review to Janssen for Apalutamide as a Treatment for Non-Metastatic Castration-Resistant Prostate Cancer

Janssen Biotech, Inc. (Janssen) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation for the New...

Dec 12, 2017, 06:45 ET DARZALEX® (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible

Janssen Research & Development, LLC today announced data from the Phase 3 ALCYONE study, showing that DARZALEX® (daratumumab) in combination with...

Dec 11, 2017, 16:15 ET New Data for DARZALEX® (daratumumab) Presented at ASH 2017 Showed Feasibility of Subcutaneous Use and Promise of DARZALEX as a Treatment for Smoldering Multiple Myeloma

Janssen Research & Development, LLC today announced new data from the Phase 1b PAVO clinical study, which demonstrated that the subcutaneous delivery ...

Dec 09, 2017, 11:05 ET Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3½-Year Follow-Up Data of IMBRUVICA® (ibrutinib)

Today, Janssen Research & Development, LLC (Janssen) announced results of a pooled analysis of relapsed/refractory (r/r) mantle cell lymphoma (MCL)...

Nov 21, 2017, 10:37 ET Janssen Submits Application to U.S. FDA to Expand Indication for DARZALEX® (daratumumab) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma who are Transplant Ineligible

Janssen Biotech, Inc. today announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug...

Oct 11, 2017, 08:44 ET Janssen Submits New Drug Application to U.S. FDA for Apalutamide (ARN-509) to Treat Men with Non-Metastatic Castration-Resistant Prostate Cancer

Janssen Biotech, Inc. today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for...

Sep 22, 2017, 16:15 ET Janssen Receives Complete Response Letter From U.S. FDA For Sirukumab Biologics License Application

Janssen Biotech, Inc. (Janssen) announced today that it has received a complete response letter from the U.S. Food and Drug Administration (FDA) for...

Sep 14, 2017, 16:03 ET Janssen Submits Supplemental New Drug Application to U.S. FDA for ZYTIGA® (abiraterone acetate) to Treat Men with Earlier Stages of Metastatic Prostate Cancer

Janssen Biotech, Inc. today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA)...

Aug 31, 2017, 08:05 ET Multiple Myeloma Patients and Supporters Embark on Cross-Country Journey to Raise Awareness and Accelerate Cancer Research

On September 3, a team of cyclists personally impacted by multiple myeloma will depart Los Angeles, California on a 3,400-mile ride ending in...

Aug 02, 2017, 16:49 ET FDA Advisory Committee Does Not Recommend Approval Of Sirukumab For The Treatment Of Moderately To Severely Active Rheumatoid Arthritis

Janssen Biotech, Inc. announced today that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) did not recommend approval ...

Aug 02, 2017, 13:32 ET U.S. FDA Approves IMBRUVICA® (ibrutinib) as First and Only Approved Treatment for Adult Patients with Chronic Graft-Versus-Host-Disease (cGVHD) After Failure of One or More Lines of Systemic Therapy

The U.S. Food and Drug Administration (FDA) has approved IMBRUVICA® (ibrutinib) for the treatment of adult patients with chronic...

Jul 13, 2017, 16:10 ET Janssen Announces U.S. FDA Approval Of TREMFYA™ (Guselkumab) For The Treatment Of Moderate To Severe Plaque Psoriasis

Janssen Biotech, Inc.(Janssen) announced today that the U.S. Food and Drug Administration (FDA) has approved TREMFYA™ (guselkumab) for the treatment...

Jun 16, 2017, 14:15 ET DARZALEX® (daratumumab) Approved by the U.S. FDA in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Who Have Received At Least Two Prior Therapies

Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the immunotherapy DARZALEX® (daratumumab) in...
Actress Katie Lowes Reveals Her Journey With Psoriasis For The First Time Through "Psoriasis: The Inside Story" Awareness Campaign

Mar 17, 2017, 08:00 ET Actress Katie Lowes Reveals Her Journey With Psoriasis For The First Time Through "Psoriasis: The Inside Story" Awareness Campaign

Janssen Biotech, Inc. and the National Psoriasis Foundation (NPF) announced today the launch of Psoriasis: The Inside Story, a campaign that aims to...

Feb 17, 2017, 07:00 ET New Data Shows STELARA® (ustekinumab) Maintained Clinical Response And Remission After Two Years Of Treatment In Adult Patients With Moderately To Severely Active Crohn's Disease

Janssen Biotech, Inc. announced today new two-year data from the ongoing IM-UNITI long-term extension (LTE) study evaluating the efficacy and safety...

Jan 19, 2017, 06:05 ET IMBRUVICA® (ibrutinib) Approved by FDA for Marginal Zone Lymphoma (MZL) Patients Who Require Systemic Therapy and Have Received At Least One Prior Anti-CD20-Based Therapy

The U.S. Food and Drug Administration (FDA) has approved IMBRUVICA® (ibrutinib) for the treatment of patients with marginal zone lymphoma (MZL) who...

Jan 05, 2017, 06:59 ET Janssen Enters Immunotherapy Clinical Collaboration with Bristol-Myers Squibb to Evaluate daratumumab (DARZALEX®) in Combination with nivolumab (OPDIVO®)

Janssen Biotech, Inc. today announced that the company has entered a clinical trial collaboration with Bristol-Myers Squibb Company (BMS) to evaluate ...

Dec 20, 2016, 04:45 ET Janssen Submits Two Applications To FDA Seeking Approval Of SIMPONI ARIA® (golimumab) For The Treatment Of Active Psoriatic Arthritis And Active Ankylosing Spondylitis

Janssen Biotech, Inc. (Janssen) announced today the submission of two Supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug...

Dec 16, 2016, 07:45 ET Janssen Submits Application Seeking FDA Approval of STELARA® (Ustekinumab) for the Treatment of Adolescents with Moderate to Severe Plaque Psoriasis

Janssen Biotech, Inc. (Janssen) announced today the submission of a Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug...

Nov 21, 2016, 04:37 ET DARZALEX® (daratumumab) Approved by U.S. FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy

Janssen Biotech, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved DARZALEX® (daratumumab) in combination with...

Nov 17, 2016, 08:00 ET Janssen Submits Application To FDA Seeking Approval Of Anti-Interleukin-23 Monoclonal Antibody Guselkumab For The Treatment Of Moderate To Severe Plaque Psoriasis

Janssen Biotech, Inc. (Janssen) announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration...

Nov 14, 2016, 08:00 ET Two Studies Reveal Differences In Real-World Treatment Patterns In Rheumatoid Arthritis Patients Taking REMICADE® (infliximab) Compared To CT-P13 (infliximab biosimilar)

Janssen Biotech, Inc. announced today findings from two claims database studies examining treatment patterns in patients with rheumatoid arthritis...

Nov 10, 2016, 08:34 ET Janssen Announces Clinical Trial Collaboration and Supply Agreement with Amgen to Evaluate daratumumab (DARZALEX®) in Combination with carfilzomib (KYPROLIS®)

Janssen Biotech, Inc. today announced that the company has entered into a master clinical trial collaboration and supply agreement with Onyx...